
Konabos delivered a vendor-neutral DXP assessment and future-state roadmap for a global pharmaceutical company following an acquisition, enabling leadership to make an informed platform decision without disrupting compliance, governance, or digital operations.
Konabos partnered with the organization to evaluate the current and future-state viability of its digital experience platforms following acquisition. The engagement focused on assessing technology, operating models, governance, and organizational readiness across both environments, while defining realistic future-state options that balanced alignment, autonomy, compliance, and long-term scalability.
Pharmaceutical
Global
Following a corporate acquisition, the organization faced a complex platform decision under time and organizational pressure.
Konabos conducted an independent, vendor-neutral DXP assessment designed for regulated enterprise environments.
The engagement focused on enabling informed decision-making, not driving a predetermined platform outcome.